This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain
by Zacks Equity Research
The FDA's approval of VenoValve's PMA has the potential to significantly expand NVNO's portfolio of bioprosthetic solutions.
GMED Stock Might Rise From the Commercial Launch of Its ExcelsiusHub
by Zacks Equity Research
Globus Medical commercially launches ExcelsiusHub navigation system to elevate the standard for freehand navigation.
Reasons to Retain IART Stock in Your Portfolio for Now
by Zacks Equity Research
Integra's strong growth in the CSS business segment bolsters investors' confidence in the stock. Meanwhile, the weak liquidity position adds to the worry.
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2
by Zacks Equity Research
Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
by Zacks Equity Research
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
Should You Hold IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
Globus Medical, Inc. (GMED) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
by Zacks Equity Research
Investors feel optimistic about QGEN's growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is concerning.
3 Reasons Growth Investors Will Love Penumbra (PEN)
by Zacks Equity Research
Penumbra (PEN) possesses solid growth attributes, which could help it handily outperform the market.
ALGN Stock to Gain From CE Mark Win for Invisalign Palatal Expander
by Zacks Equity Research
Align Technology achieves a CE mark for the Invisalign Palatal Expander System.
End Market Growth, New Acquisitions Drive Thermo Fisher's Shares
by Zacks Equity Research
A few of its recent strategic acquisitions that are likely to drive future growth for TMO include the $3.1-billion acquisition of Olink Holdings.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio
by Zacks Equity Research
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Reasons to Retain BSX Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.
Boston Scientific Stock Set to Gain From Completion of Axonics Deal
by Zacks Equity Research
BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.
Here's Why You Should Add OMCL Stock to Your Portfolio Now
by Zacks Equity Research
A robust Advanced Services portfolio and long-term growth initiatives bode well for Omnicell.
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
by Zacks Equity Research
Exact Sciences presents new positive evidence backing the development of an MCED test.
Here's Why You Should Add RMD Stock to Your Portfolio Now
by Zacks Equity Research
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
Nevro Stock May Gain on the CE Mark Certification for HFX iQ
by Zacks Equity Research
NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025.
Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors are increasingly optimistic about LH due to its partnerships and operational discipline.
Should You Retain Hologic Stock in Your Portfolio Now?
by Zacks Equity Research
HOLX's strength in the Molecular Diagnostics wing instills optimism among investors. Yet, macro woes and currency impacts raise concerns.
Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?
by Zacks Equity Research
DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.
Here is Why Growth Investors Should Buy Penumbra (PEN) Now
by Zacks Equity Research
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Penumbra (PEN) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Implied Volatility Surging for Penumbra (PEN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Penumbra (PEN) stock based on the movements in the options market lately.